Kyle Kurpinski

Broken String Biosciences is a genomics company that is building a technology platform to drive the development of cell & gene therapies that are safer by design.

Karius sees a world where infectious disease is no longer a major threat to human health. We are a clinical metagenomics company focused on elevating patient care through microbial insights. By leveraging the power of clinical metagenomics, our vision is to create a world where every patient gets a clear and timely diagnosis.

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA. Locus Biosciences has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria. Guided by the custom Locus Bio CRISPRs, the Type-I Cas proteins work to destroy bacterial DNA and cause the bacterial targets to “self-destruct”. Locus’ platform enables the development of antimicrobials which avoid currently known resistance mechanisms while leaving non-target bacteria unharmed. Built on prokaryotic technology for prokaryotic targets, Locus is advancing its platform to create therapeutics for critical-need therapeutic areas ranging from resistant bacterial infections to the microbiome.

Broken String Biosciences is a genomics company that is building a technology platform to drive the development of cell & gene therapies that are safer by design.

Karius sees a world where infectious disease is no longer a major threat to human health. We are a clinical metagenomics company focused on elevating patient care through microbial insights. By leveraging the power of clinical metagenomics, our vision is to create a world where every patient gets a clear and timely diagnosis.

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA. Locus Biosciences has developed a platform to design and deliver custom CRISPR-Cas systems directly to specific bacteria. Guided by the custom Locus Bio CRISPRs, the Type-I Cas proteins work to destroy bacterial DNA and cause the bacterial targets to “self-destruct”. Locus’ platform enables the development of antimicrobials which avoid currently known resistance mechanisms while leaving non-target bacteria unharmed. Built on prokaryotic technology for prokaryotic targets, Locus is advancing its platform to create therapeutics for critical-need therapeutic areas ranging from resistant bacterial infections to the microbiome.

Tencent is a world-leading internet and technology company that develops innovative products and services to improve the quality of life of people around the world. Founded in 1998 with its headquarters in Shenzhen, China, Tencents guiding principle is to use technology for good. Our communication and social services connect more than one billion people around the world, helping them to keep in touch with friends and family, access transportation, pay for daily necessities, and even be entertained. Tencent also publishes some of the worlds most popular video games and other high-quality digital content, enriching interactive entertainment experiences for people around the globe. Tencent also offers a range of services such as cloud computing, advertising, FinTech, and other enterprise services to support our clients digital transformation and business growth. Tencent has been listed on the Stock Exchange of Hong Kong since 2004.